

INDEX TO SUBJECTS

Names of authors of original articles (O), editorials (E), and correspondence (C) are distinguished by large and small capital letters. Authors of abstracted articles (A), obituaries (Ob), news and notes (N), and books (B) are shown in ordinary type.

Acedapsona,		
chemoprophylaxis against leprosy with. Noordeen, S. K., <i>et al.</i>	(A)	360
Acid,		
ascorbic, effect on blood levels of DDS. Venkatesan, K., <i>et al.</i>	(A)	224
Acid-fast characteristics,		
non-cultivable bacilli, isolation of, in sphagnum and moss vegetation, by foot-pad		
technique in mice. KAZDA, J., <i>et al.</i>	(O)	1
Africa,		
Central, unclassified mycobacterial strains susceptible to dapsone, isolated from the		
environment in. PORTAELS, F.	(C)	330
plants used in the treatment of leprosy in. Nwude, N. and Ebong, O. O.	(A)	344
West, barefoot doctors fighting leprosy in.	(N)	451
—, first case of leprosy with secondary resistance to dapsone in. Pattyn, S. R.,		
<i>et al.</i>	(A)	464
American Leprosy Missions (ALM),		
administrative position announced. Brand, M. B.	(N)	451
Amyloidosis(es),		
amyloid fibril proteins, found in Papua New Guinean and other. Anders, R. F.	(A)	349
renal, in Blacks. Gold, C. H.	(A)	89
secondary, in the tropics, leprosy, filariasis and malaria as causes of. McAdam, K. P.		
W. J.	(A)	347
Antia, Dr. N. H.,		
personal.	(N)	78
Antibiotics,		
aminoglycoside . . . measurement, some aspects of. Botha, P., <i>et al.</i>	(A)	85
and suppression of lymphocyte functions in. Banck, G. and Forsgren, A.	(A)	85
Antibody(ies),		
anti-mycobacterial, <i>in vitro</i> synthesis of, in skin lesion biopsies. Lai A. Fat,		
R. F. M.	(A)	352
circulating, to connective tissue microfibrils and dermal immunoglobulin deposits, in		
leprosy. Lindner, E.	(A)	94
demonstration of, against <i>M. leprae</i> , in IgG and IgM, in pregnant and non-pregnant		
lepomatous leprosy sera. Melsom, R. and Duncan, M. E.	(A)	472
immunofluorescence test for detection of, in <i>M. tuberculosis</i> . Mahfouz, M. O., <i>et al.</i> (A)		363
in leprosy sera, assay for, reacting with RNP, using crossed immunoelectrophoresis		
with intermediate gel. STONER, G. L., <i>et al.</i>	(O)	247
leprous, intraocular production of. Campinchi, R., <i>et al.</i>	(A)	230
production, effect of clinically equivalent dapsone and rifampin doses on, and		
delayed-type hypersensitivity to sheep red blood cells, in mice. Nagata, Y. and		
Ito, T.	(A)	498
specific . . . response, impairment of Jones-Mote hypersensitivity and, against		
depolymerized flagellin, in lepomatous leprosy. Saha, K., <i>et al.</i>	(A)	473
Antigen (hepatitis),		
and infectious diseases. deVries, R. R. P. and van Rood, J. J.	(A)	99
— leprosy. NOCERA, A., <i>et al.</i>	(C)	69
—, in Thailand. Chiewsilp, P., <i>et al.</i>	(A)	99
and parasitic diseases, correlation. Delia, S., <i>et al.</i>	(A)	88
— serum protein allotypes, immunogenetic background analysis, of Japanese leprosy		
patients by. Sugiyama, K., <i>et al.</i>	(A)	502

Australia, in Egypt, in lepromatous leprosy. Sheri, S., <i>et al.</i>	(A)	229
detection of Hb _{Ag} , in leprosy patients. Goiriena de Gandarias, F. J., <i>et al.</i>	(A)	466
"e" antigen, in leprosy. Nuti, M., <i>et al.</i>	(A)	89
HLA—A, B and C, in South Indian leprosy families. Wolf, E., <i>et al.</i>	(A)	478
HLA—DR, in tuberculoid and lepromatous leprosy. Rea, T. H. and Terasaki, P. I.	(A)	473
HLA segregation of tuberculoid leprosy, confirmation of DR2 marker. van Eden, W., <i>et al.</i>	(A)	478
serum titers of surface, in hepatitis B virus infection, in leprosy. Chiron, J.-P., <i>et al.</i>	(A)	226
subtypes of HB _{Ag} , distribution and occurrence, in blood donors and patients with liver diseases and leprosy, in Tamil Nadu, India. Thyagarajan, S. P., <i>et al.</i>	(A)	468
Antigen (leprosy),		
analysis of <i>M. leprae</i> . Closs, O., <i>et al.</i>	(A)	350
and phytohaemagglutinin, simultaneous stimulation with, <i>in vitro</i> lymphocyte stimulation, in leprosy. Bjune, G.	(A)	350
characterization of <i>M. leprae</i> "specific." Gillis, T. P. and Buchanan, T. M.	(A)	505
Dharmendra, comparative study with Mitsuda. Sinha, S., <i>et al.</i>	(A)	91
—, standardization of. Sengupta, U., <i>et al.</i>	(A)	91
evaluation of <i>M. vaccae</i> to <i>M. leprae</i> . NAVALKAR, R. G., <i>et al.</i>	(O)	388
liver tissue, water soluble, cross-reactions between serum. Negassi, K., <i>et al.</i>	(A)	352
lymphocyte responses to, variation of <i>in vitro</i> , in borderline tuberculoid leprosy. BJUNE, G.	(O)	30
mycobacterial ribosomal (ribonucleoprotein [RNP]) assay for antibodies in leprosy sera reacting with, using crossed immunoelectrophoresis with intermediate gel. STONER, G. L., <i>et al.</i>	(O)	247
species-specific lipid. BRENNAN, P. J. and BARROW, W. W.	(O)	382
Antigen (miscellaneous),		
in <i>Nocardia caviae</i> , detection, cross-reacting with antigen No. 21, using a lepromatous leprosy serum pool as antibody reagent. BJORVATN, B. and KRONVALL, G.	(O)	260
insoluble, organization of allergic granulomas and dependence on. McGee, M. P., <i>et</i> <i>al.</i>	(A)	471
Argentina,		
IV Reunión Leprológica (Hansenológica) del Cono Sud and V Reunión Anual de Dermatólogos Latinoamericanos del Cono Sud take place in Buenos Aires.	(N)	212
further details on IV Reunión Leprológica (Hansenológica). Cardama, J. E.	(N)	444
Armadillo (nine-banded) (<i>Dasybus novemcinctus</i>),		
lepromin, leukocyte inhibiting factor (LIF) production, from human lymphocytes of healthy donors stimulated by. Fumarola, D., <i>et al.</i>	(A)	470
macrophages, <i>M. leprae</i> inoculated, ultrastructural features of multiplication of leprosy bacilli in. Fukunishi, Y., <i>et al.</i>	(A)	494
mycolic acids analysis, in mycobacteria from lesions of, with naturally acquired leprosy-like disease and experimental . . . leprosy. Kusaka, T., <i>et al.</i>	(A)	494
naturally acquired leprosy-like disease, joint study on. Nishiura, M., <i>et al.</i>	(A)	493
—, of wild . . . , ultrastructure of lepromatous lesions. Marchiondo, A. A., <i>et al.</i>	(A)	356
report on . . . studies in Paraguay. Gordon, G.	(N)	215
serum angiotensin-converting enzyme, transcobalamin and lysozyme in normal and lepromatous. Rea, T. H., <i>et al.</i>	(A)	98
water soluble liver tissue antigens of, and man, cross-reactions between serum proteins and. Negassi, K., <i>et al.</i>	(A)	352
Armauer Hansen Research Institute (AHRI),		
<i>AHRI Research Digest: First Ten Years of Leprosy Research, 1970–1980</i> , review of. Belehu, A., ed.	(B)	218
immunology conference held at.	(N)	447
publication of <i>AHRI Research Digest</i> announced.	(N)	212
ten years activity at, immunological aspects of leprosy, prospects for further work. HARBOE, M.	(E)	193

48, 4	<i>Subject Index—Volume 48</i>	535
Art,		
and leprosy, in South China. SKINSNES, O. K.	(C)	71
Arthritis,		
in Hansen's disease. Pernambuco, J. C. de A., <i>et al.</i>	(A)	90
poly-, in leprosy. Kuntz, J. L., <i>et al.</i>	(A)	467
Australia,		
nerve calcification caused by leprosy in Northern Territory Aborigines. Bateson, E. M. and Hargrave, J. C.	(A)	87
Austria,		
Third European Conference of Rehabilitation International planned in.	(N)	446
Autoantibodies,		
prevalence of, in Korean leprosy patients. Moon, K. C., <i>et al.</i>	(A)	231
Autoimmunity,		
a common denominator in immune complex diseases? Lewis, E. J. and Roberts, J. L.	(A)	241
Azulay, Dr. R. D.,		
personal.	(N)	212
B663,		
trial by high performance liquid chromatography for simultaneous analysis of DDS, RFP and, and main metabolites. Tsutsumi, S. and Gidoh, M.	(A)	496
Bacterial Index (BI),		
average, a reflection of patients' true condition? WARNDORFF, T.	(C)	441
BCG,		
effect of bases of nucleic acid, on growth of, and <i>M. bovis</i> and <i>M. lepraemurium</i> . Cheng, Y. T.	(A)	507
mixture of <i>M. leprae</i> and, immunological changes in indeterminate and lepromatous leprosy patients, and Mitsuda-negative contacts, after inoculation of. Convit, J., <i>et al.</i>	(A)	93
oral vaccine, tuberculin test, and infection in children under five years of age. Dias, M. H. de P. and Hayashi, A.	(A)	103
protection for newborn and young infants? ten Dam, H. G. and Hitze, K. L.	(A)	481
trial in South India for tuberculosis prevention.	(A)	242
twelve years of vaccination with, and infant leprosy, in Cuba. Abreu, A., <i>et al.</i>	(A)	476
vaccination, influence on murine leprosy, in C57BL/6 and C3H mice. Lagrange, P. H. and Hurtrel, B.	(A)	233
—, protective effect, as indicated by autopsy studies. Sutherland, I. and Lindgren, I.	(A)	242
Bedsores,		
modified water-air mattress in management of. Gupta, R. C., <i>et al.</i>	(A)	102
Belgium,		
honors Dr. S. G. Browne. Gordon, G.	(N)	334
Bible,		
<i>Leprosy in the Bible</i> . 3rd ed. Browne, S. G.	(B)	80
Biopsy,		
from skin lesions, <i>in vitro</i> synthesis of anti-mycobacterial antibodies in, in leprosy patients. Lai A. Fat, R. F. M., <i>et al.</i>	(A)	352
<i>in vitro</i> studies on, from leprosy cases. Goyle, S. and Virmani, V.	(A)	96
scrotal, in subsided lepromatous leprosy. Ramu, G. and Desikan, K. V.	(A)	96
skin, lactate dehydrogenase zymograms of, in leprosy. SAOJI, A. M., <i>et al.</i>	(O)	426
Blood,		
peripheral, monocyte function, in leprosy patients. MASUDA, A. and SCHEINBERG, M. A.	(O)	254

Blood groups,		
ABO, and leprosy, in Ethiopia. Ahmed, H. A., <i>et al.</i>	(A)	476
Bolivia,		
Ministry of Health issues HD publication.	(N)	334
Bone,		
involvement, dimorphous reaction with, of upper extremities in patient with bacterial endocarditis.	(A)	348
Brazil,		
atypical mycobacteria isolated from sources in Rio de Janeiro, bacteriological study and drug susceptibility test. Fonseca, L. de S. and Gontijo Filho, P. P.	(A)	104
—, preliminary identification of colony morphologies. Fonseca, L. de S. and Gontijo Filho, P. P.	(A)	104
Brazilian Phase III of hanseniasis prevention. Rotberg, A.	(A)	460
details of . . . meetings announced.	(N)	212
Dr. R. D. Azulay receives appointment.	(N)	212
endemic HD in São Paulo county, 1976–1977. Lombardi, C.	(A)	477
epidemiological aspects of hanseniasis, in Paraíba Valley-São Paulo. Nobrega, R. C. and Mascani, M.	(A)	101
Brobenzoxaldine,		
and broxyquinoline, therapeutic trial of a combination, in leprosy treatment. Hazra, S. K., <i>et al.</i>	(A)	223
Browne, Dr. S. G.,		
personal. Gordon, G.	(N)	76
—, Gordon, G.	(N)	334
—,	(N)	337
Broxyquinoline,		
and brobenzoxaldine, therapeutic trial of a combination, in leprosy treatment. Hazra, S. R., <i>et al.</i>	(A)	223
Burma,		
Upper, Singu area, epidemiological information on leprosy in. Martínez Domínguez, V., <i>et al.</i>	(A)	477
Cancer,		
lung, pulmonary tuberculosis and leprosy, PHA skin test in patients with, clinical significance. Kado, M., <i>et al.</i>	(A)	230
Candidiasis,		
pulmonary. Thiagarajan, V., <i>et al.</i>	(A)	230
systemic, immunodiagnosis of, mannan antigenemia detected by radioimmunoassay, in experimental and human infections. Weiner, M. H. and Coats-Stephen, M.	(A)	243
Carbamazepine,		
in neurological manifestations of leprosy. Jiménez, A. M. and Urcuyo, F. G.	(A)	228
Cauda equina syndrome,		
and ulceromutilant acropathy. Barrucand, D., <i>et al.</i>	(A)	225
Cell(s),		
mononuclear-phagocyte series (MPS), ultrastructure of, across leprosy spectrum. Ridley, M. J., <i>et al.</i>	(A)	473
Cell culture,		
attempts at <i>M. leprae</i> cultivation in. Matsuo, Y.	(A)	498
Central African Empire,		
leprosy in the. Vinet, J.	(A)	101
Chagas' disease,		
potential for immunoprophylaxis.	(A)	240
Chemoprophylaxis,		
against leprosy, with acedapson. Noordeen, S. K., <i>et al.</i>	(A)	360

Chemotherapy,		
association of . . . and immunostimulation, present evaluation, in leprosy. Saint-André, P., <i>et al.</i> (A)		344
disabilities, incidence of, after commencement of, in leprosy. Keeler, R. F. and Ryan, M. A. (A)		479
intermittent, of experimental leprosy, in mice. Colston, M. J., <i>et al.</i> (A)		222
of infectious diseases, in the Soviet Union. Pershin, G. N. (A)		344
— leprosy, discussed. (N)		335
— neuritis, in leprosy. Carayon, A. (A)		85
of pulmonary tuberculosis, clinical trial of six-month and four-month regimens. (A)		241
—, four short-course regimens, controlled clinical trial, for two durations. (A)		481
—, side-effects of drug regimens in short-course. Zierski, M. and Bek, E. (A)		363
trials reviewed, present situation in Korea. Lew, J. (A)		463
Child(ren),		
babies, of mothers with leprosy, have small placentae, low birth weights, slow growth. Duncan, M. E. (A)		465
clinically healthy, cellular immunity in, of parents with leprosy, in Northern Thailand. Nelson, K. E., <i>et al.</i> (A)		501
leprosy in. El-Zawahry, M., <i>et al.</i> (A)		234
—, in a Vietnamese adoptee. Lauer B. A., <i>et al.</i> (A)		347
—, in preschool age. Revankar, C. R., <i>et al.</i> (A)		236
tuberculin test, oral BCG vaccine, tuberculosis, in children under five years old. Dias, M. H. de P. (A)		103
twelve years of BCG vaccination, infant leprosy, in Cuba. Abreu, A., <i>et al.</i> (A)		476
Chimpanzee,		
leprosy in a, postmortem lesions. LEININGER, J. R., <i>et al.</i> (O)		414
China,		
leprosy and art in South. SKINSNES, O. K. (C)		71
leprosy in. Garrigue, R. (A)		342
— archeologically recovered bamboo book in. SKINSNES, O. K. (C)		333
Classification, of leprosy,		
application of clinical and histopathological. Sehgal, V. N., <i>et al.</i> (A)		468
location of the indeterminate form. Consigli, C. A. (A)		88
polar concept, in leprosy, today. RABELLO, F. E. (E)		318
Clofazimine,		
and thalidomide combined, treatment of steroid dependent cases of recurrent leprosy reaction. Ramu, G. and Girdhar, A. (A)		229
Colchicine,		
management of necrotizing vasculitis with. Hazen, P. G. and Beno, M. (A)		105
Colitis,		
pseudomembranous, and rifampin. Acocella, G. and Arioli, V. (A)		343
—, probably due to rifampin. Fournier, G., <i>et al.</i> (A)		222
ulcerative, treatment with thalidomide. Waters, M. F. R., <i>et al.</i> (A)		86
Collagen,		
of permanently damaged nerves, in human leprosy. JUNQUEIRA, L. C. U., <i>et al.</i> (O)		291
Concanavalin A,		
induced suppressor activity, in human leprosy. Nath, I., <i>et al.</i> (A)		352
Congresses,		
Tenth International Congress on Tropical Medicine and Malaria, Manila, Philippines. (N)		335
Third International Leprosy Congress for Arab Countries, Cairo, Egypt. (N)		334
Contacts, leprosy,		
nerve damage, in leprosy, index branch of radial cutaneous nerve in. Shetty, V. P., <i>et al.</i> (A)		354
Control, of leprosy,		
disability, as a relevant measurement of progress in. Smith, W. C. S., <i>et al.</i> (A)		479

frequency of hanseniasis, in a university hospital. Figueiredo, A. A. and Sudo, L. L. (A)	358
information system for (OMSLEP). LECHAT, M. F., <i>et al.</i> (O)	51
integration with general health services, in Maharashtra. Kapoor, P., <i>et al.</i> (A)	83
<i>Leprosy Control Services as an Integral Part of Primary Health Care Programs in Developing Countries.</i> Buchmann, H. (B)	219
organizing a program of. Browne, S. G. (A)	234
prevention and. Mohan Das, M. G. (A)	359
socio-economic conditions and leprosy, private office practice and public outpatient clinic compared, over 30-year period. Tello, E. E. (A)	349
transmission, new dimensions in understanding, impact on priorities. Davey, T. F. (A)	349
Corynebacterium,	
strain 0122, a contaminating skin. Piot, P., <i>et al.</i> (C)	211
Costa Rica,	
changes announced in HD care. (N)	334
Council for International Organizations of Medical Sciences,	
details concerning. Browne, S. G. (N)	450
Cuba,	
twelve years of BCG vaccination and infant leprosy in. Abreu, A., <i>et al.</i> (A)	476
Cultivation, mycobacteria,	
requirements for, of <i>Treponema pallidum</i> , <i>M. leprae</i> , and others. Stevens, K. M. (A)	233
<i>The in vitro Cultivation of the Pathogens of Tropical Diseases.</i> (B)	455
Dapsone (DDS),	
and anti-dapsone antibody, in circulating immune complexes, in leprosy patients. Das, P. K., <i>et al.</i> (A)	462
ascorbic acid, effect on blood levels of. Venkatesan, K., <i>et al.</i> (A)	224
carcinogenicity of, in mice and rats. Griucute, L. and Tomatis, L. (A)	463
clinically equivalent doses of rifampin and, effect on antibody production and delayed-type-hypersensitivity, to sheep red blood cells, in mice. Nagata, Y. and Ito, T. (A)	498
combined rifampin and, chemotherapy of <i>M. leprae</i> infection, in neonatally thymectomized Lewis rat. FIELDSTEEL, A. H. and LEVY, L. (O)	267
high performance liquid chromatography, for simultaneous analysis of RFP, B663 and. Tsutsumi, S. and Gidoh, M. (A)	496
mechanism of action of. HASTINGS, R. C. (E)	65
— folate blocker, studied in <i>E. coli</i> cell-free enzyme extracts, compared to sulfonamides (SA). SEYDEL, J. K., <i>et al.</i> (O)	18
100 mg daily, preventing permanent nerve damage, in reversal reaction. VAN DER MEULEN, J. (C)	208
oral activated charcoal and . . . elimination. Neuvonen, P. J., <i>et al.</i> (A)	464
oxidative effects of . . . derivative, on normal and chronic granulomatous disease polymorphonuclear function. Baehner, R., <i>et al.</i> (A)	461
reply to Dr. Van der Meulen's letter. NAAFS, B. (C)	209
secondary . . . resistance, first case of leprosy, in West Africa. Pattyn, S. R., <i>et al.</i> (A)	464
—, prevalence, in Gudiyattam Taluk (India). BALRAJ, V., <i>et al.</i> (O)	397
unclassified mycobacterial strains susceptible to, isolated from environment, in Central Africa. PORTAELS, F. (C)	330
variable bacilloscopic and morphologic indexes, in leprosy patients treated with rifampin and. Belda, W., <i>et al.</i> (A)	461
Dinitrochlorobenzene,	
responsivity in untreated leprosy, variations in, beneficial role for anergy. REA, T. H. and LEVAN, N. E. (O)	120
Disabilities,	
in leprosy, measurement of progress in leprosy control. Smith, W. C. S., <i>et al.</i> (A)	479
incidence, after commencement of chemotherapy, in leprosy. Keeler, R. F. and Ryan, M. A. (A)	479

Drug effects,		
antiinflammatory effects of several antileprosy drugs. Gidoh, M., <i>et al.</i>	(A)	462
kinetic discrimination of three sulfamethazine acetylation phenotypes. Chapron, D. J., <i>et al.</i>	(A)	222
statistical tests, results obtained by kinetic method, by proportional bactericidal method. Shepard, C. C.	(A)	492
Egypt,		
Australia antigen, in lepromatous leprosy in. Sheri, S., <i>et al.</i>	(A)	229
Third International Leprosy Congress for Arab Countries meets in.	(N)	334
Electron microscopy,		
improved embedding method, of lepromata. OKADA, S., <i>et al.</i>	(O)	408
study of tuberculoid lesions, proposal of subpolar tuberculoid leprosy. Okada, S.	(A)	506
Employment (of patients),		
causes of unemployment among agricultural laborers with leprosy. Kuppusamy, P., <i>et</i> <i>al.</i>	(A)	103
employer acceptance of the HD patient and other handicapped persons. FRIST, T. F.	(O)	303
medical certification of leprosy patients, reservation in service for physically handicapped. MEHTA, J. M.	(C)	332
Endocarditis,		
bacterial, dimorphous reaction with bone involvement of upper extremities of patient with.	(A)	348
Enzyme(s),		
studied in hanseniasis patients, activity of glutamic pyruvate transaminase, glutamic oxaloacetic transaminase. Pacin, A. and Fliess, E. L.	(A)	348
Epidemiology,		
case of leprosy, at Charity Hospital, New Orleans. McNeeley, D. F.	(A)	101
—, autochthonous. Godeau, P., <i>et al.</i>	(A)	235
early detection of infectious leprosy, role of medical personnel. Kapoor, P. and Yellapurkar, M. V.	(A)	235
endemic HD, in São Paulo County, Brazil. Lombardi, E.	(A)	477
in Bordeaux (France), 1947–1979, 82 cases managed at dermatological clinic. Texier, L., <i>et al.</i>	(A)	478
— continental France, of leprosy. Samsoen, M., <i>et al.</i>	(A)	361
— Norway, based on national patient registry. Irgens, L. M.	(A)	358
— Saudi Arabia, leprosy and leprosy care. Sebai, Z.	(A)	477
— Singu, Upper Burma, of leprosy. Martínez Domínguez, V., <i>et al.</i>	(A)	477
incidence of leprosy, in Martinique, case-finding methods. Argellies, J. L.	(A)	98
leprosy among factory workers. Ghosh, P. K.	(A)	362
— survey, in Irabu island. Saikawa, K.	(A)	361
—, in Yonaguni island. Saikawa, K.	(A)	360
of leprosy, in the Netherlands, I., 1945–1975. Leiker, D. L.	(A)	100
—, —, II. Leiker, D. L.	(A)	100
—, in the Paraíba Valley, São Paulo. Nobrega, R. C. and Mascani, M.	(A)	101
— psychiatric disturbances, among leprosy patients. KUMAR, J. H. R., <i>et al.</i>	(O)	431
socio-medical characteristics of HD patients. Kelman, H. R. and Kavalier, F.	(A)	362
Erythema multiforme,		
bacterial endotoxin (lipopolysaccharide) as a cause of. Shelley, W. B.	(A)	241
Erythema nodosum leprosum (ENL),		
coagulation abnormalities in patients with. Wirawan, R., <i>et al.</i>	(A)	468
Eschericia coli,		
cell free enzyme extracts, mechanism of action of DDS in, compared to sulfonamides. SEYDEL, J. K., <i>et al.</i>	(O)	18

Ethambutol,		
inhibition by, of mycolic acid transfer, into <i>M. smegmatis</i> cell wall. Takayama, K., <i>et al.</i>	(A)	86
Ethiopia,		
AHRI Research Digest: First Ten Years of Leprosy Research. Belehu, A., <i>et al.</i>	(B)	218
—	(N)	212
immunology conference held at AHRI.	(N)	447
leprosy and ABO blood groups in. Ahmed, H. A., <i>et al.</i>	(A)	476
ten years of immunological leprosy studies at AHRI. HARBOE, M.	(E)	193
Europe,		
leprosy returns to. Terencio de las Aguas, J.	(A)	360
Experimental leprosy,		
chemotherapeutic studies against, in mouse foot pad. Ji, B. H., <i>et al.</i>	(A)	463
inoculation with <i>M. leprae</i> in asplenic mouse. Nakamura, K. and Yogi, Y.	(A)	492
intermittent chemotherapy against, in mice. Colston, M. J., <i>et al.</i>	(A)	222
Eye(s),		
cataract surgery in leprosy patients. ffytche, T. J.	(A)	237
intraocular production of leprosy antibodies. Campinchi, R., <i>et al.</i>	(A)	230
ocular lesions in leprosy. Carrica, A., <i>et al.</i>	(A)	226
Face,		
correction of profile in persons with leprosy. Teixeira, A. C.	(A)	103
Filariasis,		
and leprosy and malaria, as causes of secondary amyloidosis, in the tropics.		
McAdam, K. P. W. J.	(A)	347
Fluorescent leprosy antibody absorption (FLA-ABS) test,		
for detecting subclinical <i>M. leprae</i> infection. Abe, M., <i>et al.</i>	(O)	109
sensitivity and specificity of, immuno-epidemiological <i>M. leprae</i> subclinical infection		
studies, in Miyako Islands. Abe, M., <i>et al.</i>	(A)	500
Foot,		
clinical evaluation and care of the insensitive. Shipley, D. E.	(A)	238
management of the insensitive. Brand, P. W.	(A)	237
tarsal bone disintegration in leprosy. Harverson, G. and Warren, A. G.	(A)	227
temperature assessment of the insensitive. Bergholdt, H. T.	(A)	237
Foot pad (mouse),		
chemotherapeutic experimental leprosy infection studies in. Ji, B. H.	(A)	463
enlargement, measure of induced immunity to <i>M. leprae</i> . SHEPARD, C. C., <i>et al.</i>	(O)	371
isolation of noncultivable acid-fast bacilli in sphagnum and moss vegetation by.		
KAZDA, J., <i>et al.</i>	(O)	1
reply to Dr. Bergel's letter. SHEPARD, C. C.	(C)	68
twenty years after Shepard's method of inoculation of <i>M. leprae</i> in mice.		
BERGEL, M.	(C)	67
France,		
continental, epidemiologic knowledge of leprosy in. Samsøen, M., <i>et al.</i>	(A)	361
epidemiologic study of 82 cases of leprosy, at Bordeaux dermatological clinic, 1947–		
1979. Texier, L., <i>et al.</i>	(A)	478
leprosy in, experience in. Bordeaux. Beylot, C., <i>et al.</i>	(A)	357
Société Française de Dermatologie meets.	(N)	447
Genetics,		
markers and leprosy, in South African Negroes, erythrocyte enzyme polymorphisms.		
Hitzeroth, H. W., <i>et al.</i>	(A)	99
of hanseniasis. Beiguelman, B.	(A)	357
— leprosy. Serjeantson, S., <i>et al.</i>	(A)	237
susceptibility to lepromatous leprosy, hypothesis. Smith, D. G.	(A)	101

Germany,		
Rehabilitation International announces available publications.(N)		212
tuberculosis/leprosy eradication project in Paraguay (GLRA and WHO sponsored) ... (N)		74
update on Malta project (GLRA and WHO sponsored).(N)		74
Gilbert, Dr. Maurice,		
obituary. Contreras Dueñas, F.(Ob)		443
Goodpasture's syndrome,		
combined plasmaphoresis and immunosuppression in treatment of. Erickson, S. B., <i>et al.</i>(A)		104
Granuloma(s),		
organization of allergic, dependence on insoluble antigen. McGee, M. P., <i>et al.</i>(A)		471
Hairless mouse (see nude mouse)		
Hand(s),		
fingers, in non-lepromatous leprosy. McDougall, A. C.(C)		210
—, sites of leprosy bacilli, in pre-relapse patients. Jopling, W. H., <i>et al.</i>(A)		228
incidence of deformities in, in leprosy. Campos, M. P., <i>et al.</i>(A)		102
isolated pathological fracture of the capitate bone. Enna, C. D.(A)		227
leprosy and thumb reconstruction by opponensplasty or phalangizing the first metacarpal. Brown, H. and Getty, P.(A)		102
Haptoglobin(s),		
phenotypes, in leprosy. Sasaki, A. M., <i>et al.</i>(O)		422
Health education,		
and leprosy. Matthews, C. M. E., <i>et al.</i>(A)		477
—, Phillips, M. A.(A)		236
Hedgehog (<i>Erinaceus europaeus</i>),		
transmission of human leprosy bacilli to. Klingmüller, G. and Sobich, E.(A)		97
Hematocrit,		
and sulfonemia, in leprosy patients. Magna, L. A., <i>et al.</i>(A)		223
Hepatitis,		
cholestatic, during treatment with INH and rifampin, toxicity of rifampin. Poupon, R. Y., <i>et al.</i>(A)		464
Hepatitis B,		
lymphocytotoxins in leprosy and asymptomatic. Serjeantson, S. and Dry, P.(A)		354
markers, in leprosy. Chiron, J.-P., <i>et al.</i>(A)		87
markers (HB _e Ag, anti-HB _e , anti-HB _c), in the blood. Chiron, J.-P., <i>et al.</i>(A)		465
relation between envelope markers of . . . and transaminasemia. Chiron, J.-P., <i>et al.</i>(A)		227
Histoid leprosy,		
ultrastructural observation. Ridley, M. J. and Ridley, D. S.(O)		135
Histology,		
and histochemistry, in striated muscle, in four categories of leprosy. Daver, S. M., <i>et al.</i>(O)		140
History,		
<i>Domus leprosa</i> , community care in medieval England. Bayliss, J. H.(A)		342
leprosy in Hawaii, scare advertising at the turn of the century. Chapman, R. F.(A)		221
— in medieval Arabic medicine. Dols, M. W.(A)		82
— since Hansen. Boughton, C. R.(A)		82
Public Health Service Leprosy Investigation Station on Molokai, Hawaii, 1909–1913. Michael, J. M.(A)		459
Hypersensitivity,		
Jones-Mote, impairment of, specific antibody response against depolymerized flagellin, in lepromatous leprosy. Saha, K., <i>et al.</i>(A)		473

Hypersensitivity, delayed-type (DTH),		
effect of clinically equivalent doses of dapsone and rifampin on antibody production and, to sheep red blood cells, in mice. Nagata, Y. and Ito, T.(A)		498
IILEP,		
XXIII General Assembly of . . . meets in London.(N)		337
Immune complex(es),		
circulating, dapsone and anti-dapsone antibody in. Das, P. K., <i>et al.</i>(A)		462
—, detection of, using human and equine C ₁ q, in leprosy patients. Kliemann, T. A. E., <i>et al.</i>(A)		351
Immunity,		
significance of . . . in leprosy. Bjune, G.(A)		469
Immunity, cell-mediated (CMI),		
evaluation in mice, studies on immune response in <i>M. lepraemurium</i> . Navalkar, R. G., <i>et al.</i>(A)		476
in a group of leprosy patients, leukocyte migration inhibition test. Garcia González, J., <i>et al.</i>(A)		93
role of macrophages in defective, factors from macrophages affecting protein synthesis and lymphocyte transformation. SALGAME, P. R., <i>et al.</i>(O)		172
—, macrophage and lymphocyte interaction. BIRDI, T. J., <i>et al.</i>(O)		178
Immunodeficiency,		
possible origin, in Virchowian Hanseniasis. Fliess, E. L.(A)		351
Immuno-electrophoresis,		
crossed, with intermediate gel, assay for antibodies in leprosy sera reacting with RNP using. STONER, G. L., <i>et al.</i>(O)		247
Immunofluorescence,		
test for detection of antibodies to <i>M. tuberculosis</i> . Mahfouz, M. O., <i>et al.</i>(A)		363
Immunoglobulin(s),		
antibodies against <i>M. leprae</i> in . . . G and M, in pregnant and nonpregnant lepromatous leprosy sera. Melsom, R. and Duncan, M. E.(A)		472
concentration, in mothers with leprosy and healthy controls and their babies, at birth. Melsom, R., <i>et al.</i>(A)		352
dermal . . . deposits, circulating antibodies to connective tissue microfibrils and, in leprosy. Lindner, E., <i>et al.</i>(A)		94
humoral factors (. . . and complement), <i>in vitro</i> synthesis of, in lesional skin of leprosy patients. Lai A. Fat, R. F. M., <i>et al.</i>(A)		93
Immunology,		
and the therapeutics of leprosy. Bullock, W. E.(A)		82
differences among active, inactive and relapsed patients, in leprosy. Koseki, M., <i>et</i> <i>al.</i>(A)		500
games parasites play, how parasites evade surveillance. Bloom, B. R.(A)		239
indirect immunoperoxidase technique in human leprosy. Alonsó, J. M., <i>et al.</i>(A)		92
“N-Factor/Anergic Margin” or resistance/susceptibility to Hanseniasis. Rotberg, A. (A)		239
rabbit red blood cell rosette formation method, thymectomized guinea pigs, immunopharmacological studies. Tsutsumi, S., <i>et al.</i>(A)		499
thoughts on, of leprosy. GOHMAN-YAHR, M.(E)		435
Immunoprophylaxis,		
Chagas’ disease, potential for.(A)		240
Immunostimulation,		
leprosy treatment by association of chemotherapy and. Saint-André, P., <i>et al.</i>(A)		344
Indeterminate leprosy,		
changes in . . . and lepromatous leprosy patients and Mitsuda-negative contacts, after inoculation of <i>M. leprae</i> and BCG mixture. Covit, J., <i>et al.</i>(A)		93
immunological studies in patients with. Fliess, E. L., <i>et al.</i>(A)		93
location of . . . form in classification of leprosy. Consigli, C. A.(A)		88

India,

- Bombay Leprosy Project issues 1978 annual report.(N) 74
 Eighth Workshop on Leprosy held by The Foundation for Medical Research.(N) 214
 XI Biennial Conference of Indian Association of Leprologists meets in Madras.
 Gordon, G.(N) 214
 Emmaus Referral Hospital and Leprosy Project.(N) 213
 Gandhi Memorial Leprosy Foundation announces courses.(N) 75
 GLRA leprosy control work in Bombay.(N) 213
 HLA—A, B and C antigens, in South Indian leprosy families. Wolf, E., *et al.*(A) 478
 Maharashtra, integration of leprosy control and general services in. Kapoor, P.,
et al.(A) 83
 Presidential address, Indian Association of Dermatologists, Venereologists and
 Leprologists. Bedi, B. M. S.(A) 458
 Schieffelin Leprosy Training and Research Centre, 1980 schedule of courses.(N) 75
 —, 1981 schedule of courses.(N) 448
 —, opens new facility.(N) 447
 secondary dapsone resistance, prevalence, in Gudiyattam Taluk. BALRAJ, V.,
et al.(O) 397
 seven year study results on BCG released.(N) 213
 Tamil Nadu, antigenic subtypes of HB₉Ag, in patients with liver disease and leprosy
 in. Thyagarajan, S. P., *et al.*(A) 468
 trial of BCG vaccines, for tuberculosis prevention, in South.(A) 242
 tuberculosis in. Nagpaul, D. R.(A) 105
 WHO, short term consultants in South.(N) 449
 —, workshop held at JIPMER.(N) 214

INH,

- cholestatic hepatitis during treatment with . . . and rifampin. Poupon, R. Y., *et al.* ... (A) 464

INTERNATIONAL JOURNAL OF LEPROSY,

- acknowledgement.(—) 107
 (—) 245
 (—) 369
 (—) 524
 available through UMI Serials Program. Gordon, G.(N) 338
 information requested from national leprosy associations for. HASTINGS, R. C.(E) 439
 reviewers, list of.(—) 453
 statement of financial condition.(—) 365
 statement of ownership, management and circulation.(—) 556

International Leprosy Association,

- new members approved.(N) 78
 organization and membership.(—) 510
 statement of financial condition.(—) 368

Iridocyclitis,

- lepromatous, diagnosed by anterior chamber paracentesis. Michelson, J. B., *et al.* ... (A) 89

Isonicotinic acid,

- hydrazide, isolation culture of seven strains of *M. lepraemurium* and, or rifampin
 resistant Hawaiian strain. Mori, T. and Kohsaka, K.(A) 232

Italy,

- Health Cooperation Papers*, published in. Nunzi, E., ed.(B) 340

Japan,

- Dr. S. G. Browne honored. Gordon, G.(N) 76
 Dr. W. F. Kirchheimer speaks. Gordon, G.(N) 215
 immunogenetic background of leprosy patients in, by HLA and serum protein
 allotypes. Sugiyama, K., *et al.*(A) 502
 Japan Shipbuilding Industry Foundation contributes to WHO.(N) 214
 Miyako Islands, FLA-ABS test in three villages of, immuno-epidemiological studies
 on subclinical infection with *M. leprae*. Abe, M., *et al.*(A) 500
 XVI International Congress of Dermatology announced.(N) 76

Kala-azar,		
immunological responses in Indian. Aikat, B. K., <i>et al.</i>	(A)	238
Kenya,		
short-course (6 month) chemotherapy regimens for pulmonary tuberculosis in nomads in. Aluoch, J. A.	(A)	239
Korea,		
chemotherapeutic trials on leprosy in, review. Lew, J.	(A)	463
prevalence of autoantibodies in . . . leprosy patients. Moon, K. C.	(A)	231
Wilson Leprosy Center & Rehabilitation Hospital issues 1979 annual report.	(N)	334
Laviron, Paul,		
obituary. Sansarricq, H.	(Ob)	66
Leishmanin (Montenegro reaction),		
transfer of delayed hysensitivity to. Mendes, E.	(A)	105
Lepromatous leprosy,		
—, Busch, S. and Korting, G. W.	(A)	346
activity and effective serum level of repository sulfones (DADDS) in. Anand, L. C. and Rathore, B. S.	(A)	85
and contact dermatitis. Jerez, J., <i>et al.</i>	(A)	466
Australia antigen in, in Egypt. Sheri, S., <i>et al.</i>	(A)	229
extensive skin necrosis in, in reactive exacerbation. Bourgeois-Droin, Ch., <i>et al.</i>	(A)	87
genetic hypothesis for susceptibility to. Smith, D. G.	(A)	101
histopathology of the spleen in. REA, T. H., <i>et al.</i>	(O)	285
immunological changes in indeterminate and . . . patients and Mitsuda-negative contacts, after inoculation of <i>M. leprae</i> and BCG mixture. Convit, J., <i>et al.</i>	(A)	93
<i>in situ</i> activation of suppressor T-cells in . . . patients. Mehra, V., <i>et al.</i>	(A)	502
in the head-neck region. Koch, U., <i>et al.</i>	(A)	347
<i>in vivo</i> effects of propranolol on some cellular and humoral immune functions in a group of patients with. Anderson, R., <i>et al.</i>	(A)	469
infiltration of lower abdominal skin in. Mahapatra, S. B.	(A)	467
intermittent rifampin therapy in. Girdhar, B. K., <i>et al.</i>	(A)	343
laparoscopic aspects of. Herrerias, J. M., <i>et al.</i>	(A)	466
LH, FSH responses to GnRH in. Dash, R. J., <i>et al.</i>	(A)	88
model of Schwann cell pathology and lysosomal activity. Dastur, D. K. and Porwal, G. L.	(A)	470
paranasal sinuses in. Barton, R. P. E. and McDougall, A. C.	(A)	226
—, radiologic changes in. Barton, R. P. E.	(A)	226
PBL transformation to testis in patients with. Wall, J. R., <i>et al.</i>	(A)	95
phagocytosis in leprosy, defective adhesive and endocytic abilities of circulating leukocytes in. ROJAS-ESPINOSA, O., <i>et al.</i>	(O)	159
reduction of subset of T cells bearing Fc receptors for IgG in. Singh, S. and Nath, I.	(A)	473
role of macrophages in defective cell-mediated immunity in, factor(s) from macrophages affecting protein synthesis and lymphocyte transformation. SALGAME, P. R., <i>et al.</i>	(O)	172
—, macrophage and lymphocyte interaction. BIRDI, T. J., <i>et al.</i>	(O)	178
scrotal biopsy in subsided cases of. Ramu, G. and Desikan, K. V.	(A)	96
Lepromin,		
armadillo, double blind trials to determine late reactivity of leprosy patients and unaffected persons to, compared to human. BECHELLI, L. M., <i>et al.</i>	(O)	126
—, leukocyte inhibiting factor (LIF) production from human lymphocytes of healthy donors stimulated by. Fumarola, D., <i>et al.</i>	(A)	470
-induced suppressor cells in patients with leprosy. Mehra, V., <i>et al.</i>	(A)	94
lymphocyte sensitization to, in patients with polar types of leprosy. Podoplelov, I. I. and Selezneva, S. P.	(A)	472
nature and familial characteristics of . . . sensitivity. Kundu, S. K., <i>et al.</i>	(A)	235
Leprosy,		
—, Bryceson, A. and Pfaltzgraff, R. E.	(B)	339

— Dharmendra.	(B)	339
— Grove, D. I.	(A)	459
— Klingmüller, G.	(B)	340
a modern enigma. Beson, C. A.	(A)	342
and art in South China. SKINSNES, O. K.	(C)	71
— fertility. Smith, D. G. and Guinto, R. S.	(A)	91
— pregnancy. Coudert, J., <i>et al.</i>	(A)	227
— the nervous system. Hentschel, B.	(A)	466
autochthonous. Godeau, P., <i>et al.</i>	(A)	235
child. El-Zawahry, M. and El-Zawahry, K.	(A)	234
circulating complexes in, studied by platelet aggregation test. Wager, O., <i>et al.</i>	(A)	95
<i>Clinical Leprosy</i> . Sehgal, V. N.	(B)	454
cough reflex in. Malik, S. K., <i>et al.</i>	(A)	89
duration of treatment for "disease arrest" of non-lepromatous, relapse rate.		
Ekambaram, V.	(A)	234
frequency of, in a university hospital. Figueiredo, A. A. and Sudo, L.	(A)	358
in a Vietnamese adoptee. Lauer, B. A., <i>et al.</i>	(A)	347
in archeologically recovered bamboo book in China. SKINSNES, O. K.	(C)	333
in Indochinese refugees. Bourne, A. J., <i>et al.</i>	(A)	465
in the Central African Empire. Vinet, J.	(A)	101
indigenous, in Sicily. Guarneri, G., <i>et al.</i>	(A)	476
kidney transplantation in. Mocelin, A. J., <i>et al.</i>	(A)	89
malnutrition and. Edelman, R.	(A)	88
neural. Carrillo Casaux, D. and Carrillo Montesinos, J. M.	(A)	96
pathological manifestations of. Kasili, E. G., <i>et al.</i>	(A)	231
pathology of spinal cord in. Koya, G. and Arakawa, I.	(A)	467
platelet adhesiveness in. Parvez, M., <i>et al.</i>	(A)	94
relation of vascular and osseous changes in. Johnson, A. C., <i>et al.</i>	(A)	466
research, recent developments in. Kansky, A.	(A)	342
serum calcium and magnesium in. Nigam, P., <i>et al.</i>	(A)	468
— lipid profile in. Sritharan, V., <i>et al.</i>	(A)	230
<i>Society and Leprosy</i> . Mutatkar, R. K.	(B)	454
strategy of early detection of infectious, role of medical personnel. Kapoor, P. and		
Yellapurkar, M. V.	(A)	235
tuberculosis and. Pattyn, S. R.	(A)	83
— Sutherland, I.	(A)	84
The Leprosy Study Centre,		
ceases operations.	(N)	450
Lesion(s),		
cutaneous, due to <i>M. kansasii</i> . Bolivar, R., <i>et al.</i>	(A)	240
lichen planus-like, caused by thiocetazone. Mani, M. Z., <i>et al.</i>	(A)	344
ocular, in leprosy. Carrica, A., <i>et al.</i>	(A)	226
of the index branch of the radical cutaneous nerve, in early leprosy. Shetty, V. P., <i>et</i>		
<i>al.</i>	(A)	354
pathogenesis of the skin, application of periodic acid-carbol pararosanilin, periodic		
acid-methenamine silver stains. Harada, K. and Kasai, T.	(A)	506
sciatic nerve, in <i>M. leprae</i> inoculated mice, nerve conduction velocity correlates.		
Shetty, V. P., <i>et al.</i>	(A)	354
skin, <i>in vitro</i> synthesis of anti-mycobacterial antibodies in biopsies from, of leprosy		
patients. Lai A. Fat, R. F. M., <i>et al.</i>	(A)	352
Leukocytes,		
defective adhesive and endocytic abilities of circulating, phagocytosis in leprosy, in		
lepromatous leprosy. ROJAS-ESPINOSA, O., <i>et al.</i>	(O)	159
Lewis rat(s),		
combined rifampin and dapsone chemotherapy of <i>M. leprae</i> infection of the		
neonatally thymectomized. FIELDSTEEL, A. H. and LEVY, L.	(O)	267
neonatally thymectomized, compared to congenitally athymic nude rat, with respect		
to <i>M. leprae</i> infection. Fieldsteel, A. H., <i>et al.</i>	(A)	491

Liver,		
function tests, in tuberculoid leprosy. Koranne, R. V., <i>et al.</i>	(A)	347
Long, Esmond Ray,		
obituary. Binford, C. H.	(Ob)	322
Lucio's phenomenon,		
—, Pursley, T. V., <i>et al.</i>	(A)	229
Lymph node(s),		
bacteriological and morphological indices in, by needle aspiration. Kaur, S., <i>et al.</i> ...	(A)	346
involvement, in tuberculoid leprosy. Koranne, R. V., <i>et al.</i>	(A)	231
Lymphocyte(s),		
antibiotics and suppression of . . . function, <i>in vitro</i> . Banck, G. and Forsgren, A.	(A)	85
human, leukocyte inhibiting factor (LIF) production from, of healthy donors, stimulated by armadillo lepromin. Fumarola, D., <i>et al.</i>	(A)	470
mixed . . . reaction, factors contributing to impairment, in leprosy. Han, S. H., <i>et al.</i> (A)	(A)	471
responses, variation of <i>in vitro</i> , to <i>M. leprae</i> antigen, in bo. cerline tuberculoid leprosy patients. BJUNE, G.	(O)	30
sensitization, to lepromin, in patients with polar types of leprosy. Podoplelov, I. I. and Selezneva, S. P.	(A)	472
stimulation, <i>in vitro</i> , simultaneously with <i>M. leprae</i> antigens and phytohemagglutinin, in leprosy. Bjune, G.	(A)	350
T and B, content of, in blood of patients with polar types of leprosy. Selezneva, S. P. and Podoplelov, I. I.	(A)	232
—, dynamics of, in process of infection, quantitative cytochemical data. Trofimov, G. K., <i>et al.</i>	(A)	106
Lymphocytotoxins,		
in leprosy, in asymptomatic hepatitis B virus infection. Serjeantson, S. and Dry, P. (A)	(A)	354
Lysosome(s),		
. . . contrasts in the immunological polar dichotomy of leprosy. Skinsnes, O. K.	(A)	355
Macrophage(s),		
behavior, to <i>M. leprae</i> , tissue culture study. Veliath, A. J., <i>et al.</i>	(A)	94
cellular immunity and phagocytic activity of, in 63 cases of leprosy.	(A)	470
defective T cell-, interaction in leprosy. Hirschberg, H. and Bergh, O.	(A)	471
function, in severe protein energy malnutrition. Bhaskaram, P.	(A)	479
of <i>M. leprae</i> inoculated armadillos, ultrastructural features of multiplication of leprosy bacilli. Fukunishi, Y., <i>et al.</i>	(A)	494
role, in defective cell-mediated immunity, in lepromatous leprosy, factors from . . . affecting protein synthesis. SALGAME, P. R., <i>et al.</i>	(O)	172
—, —, —, . . . and lymphocyte interaction. BIRDI, T. J., <i>et al.</i>	(O)	178
Madagascar,		
<i>Bibliographie Analytique des Travaux de L'Institut Pasteur de Madagascar—1898–</i> 1978. Coulanges, P. and Coulanges, M.	(A)	339
Malaria,		
leprosy, filariasis and, causes of secondary amyloidosis, in the tropics. McAdam, K. P. W. J.	(A)	347
Malaysia,		
Fourth Regional Conference on Dermatology in.	(N)	76
personalities in leprosy work in. Pettit, J. M. S.	(N)	76
status of Sungei Buloh Leprosarium. Pettit, J. M. S.	(N)	76
unusual reaction to intramuscular sulfone, in two leprosy patients in. LAING, A. B. G.	(C)	70
Mali,		
The Marchoux Institute. Saint André, P.	(A)	343
Malnutrition,		
and leprosy. Edelman, R.	(A)	88

Mangabey monkey (<i>Cercoebus</i> sp.), naturally acquired leprosy in. Meyers, W. M., <i>et al.</i>	(A)	495
Martinique and Guadeloupe, IV Congrès de Léprologie meets in.	(N)	215
incidence of leprosy in. Argellies, J. L.	(A)	98
Mental illness, psychiatric disturbances in leprosy patients, epidemiological study. KUMAR, J. H. RANJIT and VERGHESE, A.	(O)	431
Mexico, XXXIII General Assembly of the Mexican Association against Leprosy elects officers.	(N)	335
Mice, does <i>M. leprae</i> behave as an intracellular parasite in? Akiyama, T. and Yamaura, N.	(A)	503
suppressor T cells induced with mycobacterial infection in. Tokunaga, T. and Nakamura, R. M.	(A)	503
Microbiology, atypical mycobacteria, isolated from human sources, in Rio de Janeiro, bacteriological study and drug susceptibility test. Fonseca, L. de S. and Gontijo Filho, P. P.	(A)	104
—, —, —, preliminary identification of colony morphologies. Fonseca, L. de S. and Gontijo Filho, P. P.	(A)	104
identification problems of strain 0122. COCITO, C. and DELVILLE, J.	(C)	442
of human origin, isolated in 1975–1976, in Bobo-Dioulasso (Upper Volta). Rey, J. L. and Villon, A.	(A)	106
Minocycline, <i>in vitro</i> antimycobacterial activity of. Tsukamura, M.	(A)	363
Monocyte(s), peripheral blood . . . function, in leprosy patients. MASUDA, A. and SCHEINBERG, M. A.	(O)	254
Morphological Index (MI), do the average bacterial and . . . indices reflect the patients' true condition? WARNDORFF, T.	(C)	441
Mucosa, nasal, borderline tuberculoid leprosy with a "lepromatous" nodule of. Barton, R. P. E., <i>et al.</i>	(A)	345
Muscle, soleus, Hoffmann reflex of. Seville, A.	(A)	349
striated, in four categories of leprosy, fine structural changes. DASTUR, D. K. and DAVER, S. M.	(O)	149
—, —, histology and histochemistry. DAVER, S. M., <i>et al.</i>	(O)	140
<i>Mycobacterium bovis</i>, BCG, <i>M. lepraemurium</i> , effect of bases of nucleic acid on growth of. Cheng, Y. T. (A)	(A)	507
<i>Mycobacterium kansasii</i>, cutaneous lesions due to. Bolivar, R., <i>et al.</i>	(A)	240
<i>Mycobacterium komossense</i> sp. nov., —, Kazda, J. and Müller, K.	(A)	480
<i>Mycobacterium leprae</i>, adjuvant immunotherapy on infection with, and <i>M. marinum</i> , effects. Krahenbuhl, J. L., <i>et al.</i>	(A)	504
antigenic analysis of. Closs, O., <i>et al.</i>	(A)	350
— evaluation of <i>M. vaccae</i> in relation to. NAVALKAR, R. G., <i>et al.</i>	(O)	388
antigens and phytohaemagglutinin, <i>in vitro</i> lymphocyte stimulation with. Bjune, G. ...	(A)	350
armadillo-derived, multiplication of acid-fast bacilli in nude mice inoculated with. Hastings, R. C., <i>et al.</i>	(A)	490

attempt at <i>in vitro</i> cultivation, 23 positive cultures from 13 leprosy cases. Cao, S. N., <i>et al.</i>	(A)	475
behavior of macrophages to, tissue culture study. Veliath, A. J., <i>et al.</i>	(A)	94
biochemical alteration in cells following phagocytosis of. MAHADEVAN, P. R. and ANTIA, N. H.	(O)	167
characterization of . . . "specific" antigens. Gillis, T. P. and Buchanan, T. M.	(A)	505
combined rifampin and dapsone chemotherapy of . . . infection, of neonatally thymectomized Lewis rat. FIELDSTEEL, A. H. and LEVY, L.	(O)	267
cultivation of, in cell culture, attempts. Matsuo, Y.	(A)	498
— requirements for <i>Treponema pallidum</i> , . . . , other microbial and mammalian microaerophilic cells. Stevens, K. M.	(A)	233
demonstration of antibodies against, both in IgG and IgM, in sera from pregnant and non-pregnant lepromatous leprosy patients. Melson, R. and Duncan, M. E.	(A)	472
detection of antigen in <i>Nocardia caviae</i> cross-reacting with mycobacterial antigen No. 21 in, lepromatous leprosy serum pool used as antibody reagent. BJORVATN, B. and KRONVALL, G.	(O)	260
does . . . behave as an intracellular parasite in mice? Akiyama, T. and Yamaura, N.	(A)	503
effects of soluble starch lecithin and vitamins on <i>in vitro</i> growth of <i>M. lepraemurium</i> and. Nakamura, M.	(A)	507
evidence for species specific lipid antigens in. BRENNAN, P. J. and BARROW, W. W.	(O)	382
fluorescent leprosy antibody absorption (FLA-ABS) test for detecting subclinical infection with. ABE, M., <i>et al.</i>	(O)	109
foot pad enlargement as a measure of induced immunity to. SHEPARD, C. C., <i>et al.</i> (O)		371
freezing and storage in liquid nitrogen on viability and growth of, effect. Colston, M. J. and HILSON, G. R. F.	(A)	475
innoculation of mixture of . . . and BCG, immunological changes in indeterminate and lepromatous leprosy patients. Mitsuda-negative contacts after. Convit, J., <i>et al.</i>	(A)	93
metabolic inhibitors of host-tissue origin in. Prabhakaran, K., <i>et al.</i>	(A)	96
microscopic counts carried out on, and <i>M. tuberculosis</i> suspension, three staining procedures compared. COLLINS, F. M., <i>et al.</i>	(O)	402
neonatally thymectomized Lewis rat (NTLR) compared to congenitally athymic nude rat with respect to infection with. Fieldsteel, A. H., <i>et al.</i>	(A)	491
neural predilection of, in leprosy. Stoner, G. L.	(A)	94
purification procedures on viability of, effect. PRABHAKARAN, K., <i>et al.</i>	(C)	330
reply to Dr. Bergel's letter to the editor. SHEPARD, C. C.	(C)	68
Shepard's method of inoculation of, in foot pads of mice, twenty years after. BERGEL, M.	(C)	67
studied in tissue culture. Nomaguchi, H., <i>et al.</i>	(A)	508
variation of <i>in vitro</i> lymphocyte responses to . . . antigen, in borderline tuberculoid leprosy patients. BJUNE, G.	(O)	30
viability of, effect of ultraviolet rays and sunlight. Wang, H. Y. and Huang, H. S.	(A)	475
<i>Mycobacterium lepraemurium</i>,		
active or passive acquired resistance after . . . infection, in C57BL/6 and C3H/HeN mice. Lagrange, P. H.	(A)	97
effect of bases of nucleic acid on growth of <i>M. bovis</i> , BCG and. Cheng, Y. T.	(A)	507
— — soluble starch lecithin and vitamins, on <i>in vitro</i> growth of . . . and <i>M. leprae</i> . Nakamura, M.	(A)	507
growth and drug sensitivity of, by tissue culture applying monolayer and agar suspension technique. NOMAGUCHI, H., <i>et al.</i>	(O)	277
immune response to, cell-mediated immune response in mice evaluated. Navalkar, R. G., <i>et al.</i>	(A)	476
influence of BCG vaccination on murine leprosy in C57BL/6 and C3H mice. Lagrange, P. H. and Hurtrel, B.	(A)	233
<i>in vitro</i> cultivation and characterization of. PATTYN, S. R. and PORTAELS, F.	(O)	7
isolation culture of seven strains of . . . and isonicotinic acid hydrazide or rifampin resistant Hawaiian strain. Mori, T. and Kohsaka, K.	(A)	232
pathogenicity of cultivated murine leprosy bacilli of Hawaiian-Ogawa strain in mice,		

visceral lesions in mice produced by intraperitoneal infection. Kawaguchi, Y., <i>et al.</i>	(A)	96
serum protein fraction of mice inoculated with drug resistant murine leprosy bacilli. Nakagawa, K., <i>et al.</i>	(A)	234
<i>Mycobacterium marinum</i>,		
effects of adjuvant immunotherapy on infection with <i>M. leprae</i> and. Krahenbuhl, J. L., <i>et al.</i>	(A)	504
<i>Mycobacterium smegmatis</i>,		
inhibition by ethambutol of mycolic acid transfer into the cell wall of. Takayama, K., <i>et al.</i>	(A)	86
<i>Mycobacterium sphagni</i> sp. nov.,		
— Kazda, J.	(A)	479
<i>Mycobacterium tuberculosis</i>,		
comparison of plain egg medium with Löwenstein-Jensen medium in isolation of, from sputum. Venkataraman, P., <i>et al.</i>	(A)	243
immunofluorescence test for detection of antibodies to. Mahfouz, M. O., <i>et al.</i>	(A)	363
microscopic counts carried out on <i>M. leprae</i> and . . . suspensions, three staining procedures. COLLINS, F. M., <i>et al.</i>	(O)	402
<i>Mycobacterium vaccae</i>,		
antigenic evaluation of, in relation to <i>M. leprae</i> . NAVALKAR, R. G., <i>et al.</i>	(O)	388
Mycolic acid(s),		
analysis, in mycobacteria isolated from lesions of armadillos with naturally acquired leprosy-like disease and experimental armadillo leprosy. Kusaka, T., <i>et al.</i>	(A)	494
transfer, inhibition by ethambutol of, into <i>M. smegmatis</i> cell wall. Takayama, K., <i>et al.</i>	(A)	86
Nepal,		
Kathmandu workshop on leprosy held. Browne, S. G.	(N)	77
leprosy in peripheral nerves, histopathological findings in 119 untreated patients in. Pedley, J. C., <i>et al.</i>	(A)	353
Nephritis,		
rifampin-induced tubulo-interstitial. Min, K. U., <i>et al.</i>	(A)	223
Nerve(s),		
calcification caused by leprosy in Northern Territory Aboriginals. Bateson, E. M. and Hargrave, J. C.	(A)	87
collagen of permanently damaged, in human leprosy. JUNQUEIRA, L. C. U., <i>et al.</i> ...	(O)	291
cubital, motor transmission velocity of, in patients with lepra reaction, 30-year observations during thalidomide treatment. Sheskin, J. and Yaar, I.	(A)	91
electrophysiological evidence for motor unit impairment during leprosy treatment. Linois, H. and Seville, A.	(A)	362
evolution of damage in leprosy. Antia, N. H., <i>et al.</i>	(A)	350
greater auricular, in presumably non-leprous British soldiers. Lynch, P. and Johnston, J. H.	(A)	467
peripheral, involvement in leprosy, neuropathological study of autopsy cases. Mukoyama, M. and Sasaki, N.	(A)	472
—, leprosy in, histopathological findings in 119 untreated patients in Nepal. Pedley, J. C., <i>et al.</i>	(A)	353
permanent damage, in reversal reaction, DDS 100 mg daily preventing. VAN DER MEULEN, J.	(C)	208
radial cutaneous, lesions of index branch of, in early leprosy. Shetty, V. P., <i>et al.</i> ...	(A)	354
—, observations of index branch of, in leprosy contacts. Shetty, V. P., <i>et al.</i>	(A)	354
reply to Dr. Van der Meulen's letter to the editor. NAAFS, B.	(C)	209
sciatic lesions, in <i>M. leprae</i> inoculated mice, nerve conduction velocity correlates. Shetty, V. P., <i>et al.</i>	(A)	354
thickened, in a leprosy endermic region, clinical and histological study. Srinivas, H. V., <i>et al.</i>	(A)	355

—, —, ultrastructural and tease fiber study. Mehta, L. N., <i>et al.</i>	(A)	352
ulnar, decompression by medial epicondylectomy of the humerus. Oommen, P. K. ...	(A)	103
—, surgery on, in leprosy. Palande, D. D.	(A)	363
Nerve culture,		
organized, DNA synthesis in Schwann cells, in presence of <i>M. leprae</i> . MUKHERJEE, R., <i>et al.</i>	(O)	189
—, technique to study effect of <i>M. leprae</i> infection. MUKHERJEE, R., <i>et al.</i>	(O)	183
Neuritis,		
chemotherapy of, in leprosy. Carayon, A.	(A)	85
microangiopathic, in leprosy. Carayon, A.	(A)	92
new approach to relief of pain in. Mehta, J. M., <i>et al.</i>	(A)	228
segmental necrotizing granulomatous, in leprosy. CHANDI, S. M., <i>et al.</i>	(O)	41
Neuropathy,		
somatosensory and autonomic, only manifestation of long standing leprosy. Gadoth, N., <i>et al.</i>	(A)	227
<i>Nocardia caviae</i>,		
detection of antigen in, cross-reacting with mycobacterial antigen No. 21 in <i>M. leprae</i> , using a lepromatous leprosy serum pool as antibody reagent. BJORVATN, B. and KRONVALL, G.	(O)	260
Norway,		
leprosy in, epidemiological study based on national patient registry. Irgens, L. M. ...	(A)	358
medical researcher position available at AHRI.	(N)	449
Norwegian scabies,		
what is your diagnosis?	(A)	92
Nude mice,		
as an experimental lepromatous leprosy model, lepromatoid lesions in mystacial vibrissae located site of injection. Nakamura, K. and Yogi, Y.	(A)	490
effect of DDS on, experimentally infected with <i>M. leprae</i> . Kohsaka, K., <i>et al.</i>	(A)	496
multiplication of acid-fast bacilli in, inoculated with armadillo-derived <i>M. leprae</i> . Hastings, R. C., <i>et al.</i>	(A)	490
Obituaries,		
Gilbert, Maurice. Contreras Dueñas, F.	(Ob)	443
Laviron, Paul. Sansarricq, H.	(Ob)	66
Long, Esmond Ray. Binford, C. H.	(Ob)	322
Prast, Dr. Javier Guillen. Contreras Dueñas, F.	(Ob)	443
Prieto, José Gay. Contreras Dueñas, F.	(Ob)	206
Rodríguez, José N. Guinto, R. S.	(Ob)	327
o-Diphenoloxidase,		
concentrations in leprosy. Reza, K., <i>et al.</i>	(A)	90
Pakistan,		
Dr. Ruth Pfau honored by government.	(N)	449
Papua New Guinea,		
amyloid fibril proteins found in. Anders, R. F.	(A)	349
Paraguay,		
report on armadillo studies in. Gordon, G.	(N)	215
tuberculosis/leprosy eradication project in.	(N)	74
Pfau, Dr. Ruth,		
personal.	(N)	449
Phagocytosis,		
in leprosy, defective adhesive and endocytic abilities of circulating leukocytes in lepromatous leprosy. ROJAS-ESPINOSA, O., <i>et al.</i>	(O)	159
Philippines,		
Tenth International Congress on Tropical Medicine and Malaria meets in.	(N)	335

Phlebitis,		
leprous. MUKHERJEE, A., <i>et al.</i>	(O)	48
Physical therapy,		
<i>Physical Therapy in Leprosy for Paramedicals.</i> Kelly, E. D.	(B)	219
Phytohemagglutinin,		
<i>M. leprae</i> antigens and, simultaneous stimulation with. Bjune, G.	(A)	350
Platelet(s),		
adhesiveness, in leprosy. Parvez, M., <i>et al.</i>	(A)	94
Prast, Dr. Javier Guillen,		
obituary. Contreras Dueñas, F.	(Ob)	443
Pregnancy,		
leprosy and. Coudert, J., <i>et al.</i>	(A)	227
Prieto, José Gay,		
obituary. Contreras Dueñas, F.	(Ob)	206
Prurigo nodularis,		
treatment, with thalidomide. van den Broek, H.	(A)	363
Psoriasis,		
suppressor cell function in. Sauder, D. N., <i>et al.</i>	(A)	241
Reaction,		
lepra, evaluation of thalidomide derivatives in. Sheskin, J.	(A)	86
—, motor transmission velocity of the orbital nerves in patients with. Sheskin, J. and Yaar, I.	(A)	91
—, treatment of steroid dependent cases of recurrent, with combination of thalidomide and clofazimine. Ramu, G. and Girdhar, A.	(A)	229
reply to Dr. van der Meulen's letter to the editor. NAAFS, B.	(C)	209
reversal, DDS 100 mg daily preventing permanent nerve damage in. VAN DER MEULEN, J.	(C)	208
Rehabilitation International,		
Third European Conference of, planned in Austria.	(N)	446
Renal disease,		
acute renal insufficiency caused by rifampin. Rossi, E. and Montagna, G.	(A)	86
complications, frequency of sulfone resistance, results of long-term treatment. Terencio de las Aguas, J.	(A)	86
renal amyloidosis in Blacks. Gold, C. H.	(A)	89
Rifampin,		
acute renal insufficiency caused by. Rossi, E. and Montagna, G.	(A)	86
adverse reactions to. Girling, D. J. and Hitze, K. L.	(A)	344
and dapsone, combination, chemotherapy of <i>M. leprae</i> infection of neonatally thymectomized Lewis rat. FIELDSTEEL, A. H. and LEVY, L.	(O)	267
— vitamin D metabolism. Brodie, M. J., <i>et al.</i>	(A)	461
cholestatic hepatitis during treatment with INH and. Poupon, R. Y., <i>et al.</i>	(A)	464
clinically equivalent doses of dapsone and, on antibody production and delayed-type hypersensitivity, to sheep red blood cells, in mice. Nagata, Y. and Ito, T.	(A)	498
comparative study of variable averages of bacilloscopic and morphologic indexes in virchowian hanseniasis patients treated with, and DDS. Belda, W., <i>et al.</i>	(A)	461
effect of, on the immune response in mice. Bellahsene, A. and Forsgren, A.	(A)	222
high performance liquid chromatography method for simultaneous analysis of DDS, ... B663 and main metabolites. Tsutsumi, S. and Gidoh, M.	(A)	496
<i>in vitro</i> effect of, on serum bilirubin determinations. Meisel, S., <i>et al.</i>	(A)	464
-induced tubulo-interstitial nephritis. Min, K. U., <i>et al.</i>	(A)	223
intermittent therapy, in lepromatous leprosy. Girdhar, B. K., <i>et al.</i>	(A)	343
pseudomembranous colitis and. Acocella, G. and Arioli, V.	(A)	343
— Fournier, G., <i>et al.</i>	(A)	222
"pulsed" . . . therapy, in leprosy. Girdhar, B. K. and Desikan, K. V.	(A)	223

seven years of leprosy treatment with. Terencio de las Aguas, J., <i>et al.</i>(A)	464
single dose of 1.5 gm of, with prolonged sulfone treatment, in leprosy. Languillon, J.(A)	85
Rodríguez, José N. obituary. Guinto, R. S.(Ob)	327
Rubino test, platelet aggregation test and, circulating complexes studied by platelet aggregation test, in 135 leprosy patients. Wager, O., <i>et al.</i>(A)	95
Saudi Arabia, epidemiological study of leprosy and leprosy care in. Sebai, Z. A.(A)	477
Seychelles, leprosy in the. Grainger, C. R.(A)	358
Sinus(es), paranasal, in lepromatous leprosy. Barton, R. P. E. and McDougall, A. C.(A)	226
—, —, radiological changes. Barton, R. P. E.(A)	226
Skin, abdominal, infiltration of lower, in lepromatous leprosy. Mahapatra, S. B.(A)	467
biopsies, lactate dehydrogenase zymograms of, in leprosy patients. SAOJI, A. M.(O)	426
lesional, <i>in vitro</i> synthesis of humoral factors, in leprosy patients. Lai A. Fat, R. F. M., <i>et al.</i>(A)	93
necrosis, extensive, in lepromatous leprosy in reactive exacerbation. Bourgeois-Droin, Ch., <i>et al.</i>(A)	87
slit- . . . smears, selection of sites for. Ahmed, H. A., <i>et al.</i>(A)	225
thermal sensitivity of, instrument to investigate. de Castro, I. M.(A)	346
Social and human aspects of leprosy, Brazilian Phase III of prevention of hanseniasis. Rotberg, A.(A)	460
causes of unemployment among agricultural laborers with leprosy. Kuppusamy, P., <i>et</i> <i>al.</i>(A)	103
employer acceptance of the HD patient and other handicapped persons. FRIST, T. F.(O)	303
integration of handicapped persons with leprosy into the community. Lew, J.(A)	459
medical certification of leprosy patients and reservation in service for the physically handicapped, including persons with leprosy. MEHTA, J. M.(C)	332
<i>Society and Leprosy.</i> Mutatkar, R. K.(B)	454
survey of social situation of patients at JALMA Leprosy Centre, Agra, India, medical aspects. Osaka, R.(A)	236
<i>Workshop on Human Aspects in the Treatment of Leprosy Patients.</i>(B)	80
South Africa, association of tuberculosis and leprosy in. Gatner, E. M. S., <i>et al.</i>(A)	346
genetic markers and leprosy in, erythrocyte enzyme polymorphisms. Hitzeroth, H. W., <i>et al.</i>(A)	99
Spain, two leprosy courses held at Fontilles.(N)	215
Spleen, histopathology, in a lepromatous leprosy patient. REA, T. H., <i>et al.</i>(O)	285
Stain(s), Harada's staining method for leprosy bacilli. Harahap, M. and Nasution, A. H.(A)	356
periodic acid-carbol pararosanilin and periodic acid-methenamine silver, in pathogenesis of skin lesion, in leprosy. Harada, K. and Kasai, T.(A)	506
soluble blue as a counterstain in the Ziehl-Neelsen procedure. WHEELER, P. R. and DRAPER, P.(O)	15

Sulfamethazine,		
acetylation phenotypes, kinetic discrimination of three. Chapron, D. J., <i>et al.</i> (A)		222
Sulfone(s),		
activity and effective serum level of repository . . . (DADDS), in lepromatous		
leprosy. Anand, L. C. and Rathore, B. S. (A)		85
ELISA inhibition technique for demonstration of, in body fluids, specific antibody-		
enzyme conjugate. Huikeshoven, H., <i>et al.</i> (A)		223
therapy on the outliving of hanseniasis patients. Marlet, J. M. (A)		359
unusual reaction to intramuscular, in Malaysia, in two leprosy patients. LAING,		
A. B. G. (C)		70
Sulfone resistance,		
frequency, results of long-term treatment with sulfones, renal complications. Terencio		
de las Aguas, J. (A)		86
primary, in leprosy. Jacobson, R. R. and Hastings, R. C. (A)		498
Sulfonemia,		
hematocrit and, in leprosy patients. Magna, L. A., <i>et al.</i> (A)		223
Surgery,		
cataract, in leprosy patients. ffytche, T. J. (A)		237
correction of facile profile, in leprosy. Teixeira, A. C. (A)		103
ectropion-lagophthalmos, correction of paralysis in orbital region, in leprosy. Lerner,		
R. D. and Margarido, L. C. (A)		363
in leprosy, after 25 years. Bourrel, P. (A)		362
leprosy and thumb reconstruction by opponensplasty, or phalangizing the first		
metacarpal. Brown, H. and Getty, P. (A)		102
ulnar nerve, decompression by medial epicondylectomy of the humerus. Oommen,		
P. K. (A)		103
—, in leprosy. Palande, D. D. (A)		363
Switzerland,		
availability of histamine chlorhydrate or phosphate (1:1000) for testing in suspected		
leprosy. (N)		216
chemotherapy of leprosy discussed. (N)		77
— (N)		335
Teaching and training,		
educational opportunities available at Carville. (N)		338
evaluation of interactive instructional television program, in leprosy. O'Connor,		
R. J. J. (A)		343
leprosy seminar held. (N)		337
of leprosy in medical schools, four and one-half hours in three years. McDougall,		
A. C. and Weddell, A. G. M. (C)		329
<i>The 2nd International Workshop on Leprosy Workers in Asia.</i> (B)		220
Testis,		
studies on PBL transformation to, in lepromatous leprosy. Wall, J. R., <i>et al.</i> (A)		95
Thailand,		
cellular immunity in clinically healthy children of parents with, in Northern. Nelson,		
K. E., <i>et al.</i> (A)		501
HLA antigens and leprosy in. Chiewsilp, P., <i>et al.</i> (A)		99
report of activities of McKean Rehabilitation Institute. (N)		336
Thalidomide,		
and clofazimine, combination, treatment of steroid dependent cases of recurrent lepra		
reaction with. Ramu, G. and Girdhar, A. (A)		229
derivatives, in lepra reaction. Sheskin, J. (A)		86
in treatment of recurrent, necrotic, and giant mucocutaneous apthae and apthosis.		
Mascaro, J. M., <i>et al.</i> (A)		105
motor transmission velocity of cubital nerves, in patients with lepra reaction treated		
with, 30-year observations. Sheskin, J. and Yaar, I. (A)		91

prurigo nodularis, treatment with. van den Broek, H.(A)	363
ulcerative colitis, treatment of. Waters, M. F. R., <i>et al.</i>(A)	86
The Netherlands,	
epidemiology of leprosy in, I. Leiker, D. L.(A)	100
—, II. Leiker, D. L.(A)	100
Thiacetazone,	
lichen planus-like lesions caused by. Mani, M. Z., <i>et al.</i>(A)	344
side-effect of. White, G. de L.(A)	225
Thiosemicarbazone(s),	
2-acetylpyridine, inhibition of clinically significant bacterial organisms <i>in vitro</i> .	
Dobek, A. S., <i>et al.</i>(A)	462
—, new series of compounds with antileprosy activity. Morrison, N. E., <i>et al.</i>(A)	497
Thyroxine,	
and leprosy. JOPLING, W. H.(C)	211
Tissue(s),	
connective . . . microfibrils, and dermal immunoglobulin deposits, circulating	
antibodies to, in leprosy. Lindner, E., <i>et al.</i>(A)	94
culture, growth and drug sensitivity of <i>M. lepraemurium</i> by, applying monolayer and	
agar suspension technique. NOMAGUCHI, H., <i>et al.</i>(O)	277
—, studies on <i>M. leprae</i> in. Nomaguchi, H., <i>et al.</i>(A)	508
elastic . . . system, histomorphology, in skin of human hand. Enna, C. D. and Dyer,	
R. F.(A)	102
soft- . . . research, at Carville. Beach, R. B. and Thompson, D. E.(A)	237
Transfer factor,	
for prevention of variceller-zoster infection, in childhood leukemia. Steele, R. W., <i>et</i>	
<i>al.</i>(A)	480
Transmission,	
in man. HUANG, C. L.-H.(E)	309
new dimensions of understanding, priorities in leprosy control. Davey, T. F.(A)	357
of human leprosy bacilli, to European hedgehog. Klingmüller, G. and Sobich, E.(A)	97
Trautman, John R.,	
personal. Gordon, G.(N)	217
Treatment,	
irregularity, magnitude and causes. Nigam, P., <i>et al.</i>(A)	521
medication monitor, in . . . of tuberculosis, in developing countries. Moulding, T.(A)	224
risks of treating leprosy in a general hospital. MATHAI, R., <i>et al.</i>(O)	298
Treponema pallidum,	
cultivation requirements for, and <i>M. leprae</i> , and other microbial and mammalian	
microaerophilic cells. Stevens, K. M.(A)	233
Tropical disease(s),	
new policies of WHO in research to control six. de Maar, E. W. J.(A)	458
<i>The in vitro Cultivation of the Pathogens of Tropical Diseases.</i>(B)	455
Tuberculin,	
test, oral BCG vaccine, tuberculosis infection, in children under five years. Dias, M.	
H. de P. and Hayashi, A.(A)	103
Tuberculoid leprosy,	
aspects of, chemotherapeutic trials. Noussitou, F.(A)	228
borderline, with a "lepromatous" nodule of the nasal mucosa. Barton, R. P. E., <i>et</i>	
<i>al.</i>(A)	345
electron microscopic study of tuberculoid lesions and a proposal of subpolar.	
Okada, S.(A)	506
HLA segregation of, confirmation of DR2 marker. van Eden, W., <i>et al.</i>(A)	478
liver function tests in. Koranne, R. V., <i>et al.</i>(A)	347
lymph node involvement in. Koranne, R. V., <i>et al.</i>(A)	231

systemic involvement in. Singh, R. and Koranne, R. V.(A)	232
variation of <i>in vitro</i> lymphocyte responses to <i>M. leprae</i> antigen in borderline. BJUNE, G.(O)	30
Tuberculosis,	
and leprosy. Sutherland, I.(A)	84
—, compared. Pattyn, S. R.(A)	83
—, in South Africa. Gatner, E. M. S., <i>et al.</i>(A)	346
diagnostic potentialities of enzyme-linked immunosorbent assay in, using purified tuberculin antigen. Tandon, A., <i>et al.</i>(A)	480
in India. Nagpaul, D. R.(A)	105
medication monitor in treatment of, in developing countries. Moulding, T.(A)	224
monitoring regularity of drug intake in, using simple urine tests. Burkhardt, K. R. and Nel, E. E.(A)	479
pulmonary, cellular immunity in. Byun, H. W., <i>et al.</i>(A)	240
—, chemotherapy of, clinical trial of six-month and four-month regimens.(A)	241
—, —, controlled clinical trial of four short-course regimens.(A)	481
—, —, practical application of short-course (6 month) regimens, in Kenyan nomads. Aluoch, J. A.(A)	239
—, clinical significance of PHA skin test in lung cancer, leprosy, and. Kado, M., <i>et</i> <i>al.</i>(A)	230
research in. Williams, R., <i>et al.</i>(A)	243
Turkey,	
leprosy training seminar held in.(N)	337
XII International Leprosy Congress,	
details announced.(N)	78
Ulcer(s),	
neuropathic, epithelioma cuniculatum developing in, of leprosy etiology. Ochsner, P. E., <i>et al.</i>(A)	90
plantar, treatment of, in leprosy. Campos, M. P.(A)	102
sores and, epitheliomatous degeneration of, in leprosy. Rostant, M.(A)	90
trophic, use of Fitostimoline gauzes in leprosy. Hans, G.(A)	346
U.S.S.R.,	
development of chemotherapy of infectious diseases in. Pershin, G. N.(A)	344
United Kingdom,	
Council for International Organizations of Medical Sciences, details on. Browne, S. G.(N)	450
Dr. S. G. Browne becomes Baptist leader.(N)	337
LEPRA announces 1980 Prize Essay Competition details.(N)	216
Leprosy Study Centre ceases operations.(N)	450
new ILA members approved.(N)	78
<i>Parasite Immunology</i> begins publication.(N)	78
XIII General Assembly of ILEP meets in London. Ross, W. F.(N)	337
XII International Leprosy Congress details announced.(N)	78
U.S.A.,	
ALM administrative position announced. Brand, M. B.(N)	451
Dr. John R. Trautman promoted. Gordon, G.(N)	217
Dr. N. H. Antia becomes Honorary Fellow of ACS.(N)	78
educational opportunities available at Carville.(N)	338
Heiser Program for Research in Leprosy announces 1981 research possibilities.(N)	451
IJL available through UMI serials program. Gordon, G.(N)	338
National Council for International Health establishes headquarters.(N)	78
PAHO medical position available.(N)	451
U.S.-Japan Cooperative Medical Science Program,	
Fifteenth Joint Leprosy Research Conference, Kagoshima, Japan, 9–11 October 1980.(A)	482

Upper Volta,		
mycobacteria of human origin isolated in Bobo-Dioulasso, in 1975–1976. Rey, J. L. and Villon, A.	(A)	106
Vaccination,		
active, development of, in leprosy. Convit, J., <i>et al.</i>	(A)	351
in leprosy. CONVIT, J., <i>et al.</i>	(E)	62
Vasculitis,		
necrotizing, management with colchicine. Hazen, P. G. and Beno, M.	(A)	105
Vitamin D,		
metabolism, rifampin and. Brodie, M. J., <i>et al.</i>	(A)	461
World Health Organization (WHO),		
new policies, in research on six major tropical diseases. de Maar, E. W. J.	(A)	458
short term consultants in India.	(N)	449

STATEMENT OF OWNERSHIP, MANAGEMENT, AND CIRCULATION

(Act of 12 August 1970; Section 3685, Title 39, United States Code)

1. Title of publication: INTERNATIONAL JOURNAL OF LEPROSY.
2. Date of filing: 24 September 1980.
3. Frequency of issue: Four times a year.
4. Location of known office of publication: USPHS Hospital, Carville, Louisiana 70721.
5. Location of the headquarters or general business offices of the publisher: INTERNATIONAL JOURNAL OF LEPROSY, 1262 Broad Street, Bloomfield, New Jersey 07003.
6. Names and addresses of publisher, editor, and managing editor: Publisher—The International Leprosy Association, 16 Bridgefield Road, Sutton, Surrey, England. Editor: Robert C. Hastings, M.D., Ph.D., USPHS Hospital, Carville, Louisiana 70721. Managing Editor: W. Felton Ross, M.B.B.S., P.O. Box 1097, Bloomfield, New Jersey 07003.
7. Owner: International Leprosy Association, Inc., 16 Bridgefield Rd., Sutton, Surrey, England.
8. Known bondholders, mortgagees, and other security holders owning or holding 1 percent or more of total amount of bonds, mortgages, or other securities: None.
9. For completion by nonprofit organizations authorized to mail at special rates (Section 132.122, Postal Manual): The purpose, function, and nonprofit status of this organization and the exempt status for Federal income tax purposes have not changed during preceding 12 months.
10. Extent and nature of circulation:

A. Total no. copies printed (net press run)	1349*	1400**
B. Paid circulation		
1. Sales through dealers and carriers, street vendors, and counter sales	0	0
2. Mail subscriptions	1181	1212
C. Total paid circulation	1181	1212
D. Free distribution by mail, carrier, or other means		
1. Samples, complimentary, and other free copies	49	49
2. Copies distributed to news agents but not sold	0	0
E. Total distribution (sum of C and D)	1230	1261
F. Office use, left-over, unaccounted, spoiled after printing	119	139
G. Total (sum of E and F—should equal net press run shown in A)	1349	1400

* Average no. copies each issue during preceding 12 months.

** Actual no. of copies of single issue published nearest to filing date.

—W. Felton Ross, M.B.B.S.
Executive Officer, IJL